jynarque market size forecast and market insight

“JYNARQUE Market Size, Forecast, and Market Insight - 2032” report provides comprehensive insights about JYNARQUE for Chronic Kidney Disease (CKD) in the seven major markets. A detailed picture of the JYNARQUE for CKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the JYNARQUE for CKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JYNARQUE market forecast analysis for CKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CKD.

Drug Summary

JYNARQUE (tolvaptan) is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing ADPKD. The medication has been approved as a treatment for adults with ADPKD in Japan, the EU, Canada, South Korea, Switzerland, Hong Kong, Australia, Turkey, and Taiwan. The drug is also used in hyponatremia.

Dosage and administration

The initial dosage for JYNARQUE is 60 mg orally daily, 45 mg taken on waking, and 15 mg taken 8 h later. Titrate to 60 mg plus 30 mg, then to 90 mg plus 30 mg per day if tolerated with at least weekly intervals between titrations. Patients may down-titrate based on tolerability. 

Mechanism of action

Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V2-receptor is 29 times that for the V1a receptor. Decreased binding of vasopressin to the V2-receptor in the kidney lowers adenylate cyclase activity resulting in a decrease in intracellular adenosine 3’, 5’-cyclic monophosphate (cAMP) concentrations. 

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the JYNARQUE description, mechanism of action, dosage and administration, research and development activities in Chronic Kidney Disease (CKD).
• Elaborated details on JYNARQUE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JYNARQUE research and development activities in CKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around JYNARQUE.
• The report contains forecasted sales of JYNARQUE for CKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CKD.
• The report also features the SWOT analysis with analyst views for JYNARQUE in CKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JYNARQUE Analytical Perspective by DelveInsight

In-depth JYNARQUE Market Assessment

This report provides a detailed market assessment of JYNARQUE for Chronic Kidney Disease (CKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

JYNARQUE Clinical Assessment

The report provides the clinical trials information of JYNARQUE for CKD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Chronic Kidney Disease (CKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JYNARQUE dominance.
• Other emerging products for CKD are expected to give tough market competition to JYNARQUE and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JYNARQUE in CKD.
• Our in-depth analysis of the forecasted sales data of JYNARQUE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JYNARQUE in CKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of JYNARQUE?
• What is the clinical trial status of the study related to JYNARQUE in Chronic Kidney Disease (CKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JYNARQUE development?
• What are the key designations that have been granted to JYNARQUE for CKD?
• What is the forecasted market scenario of JYNARQUE for CKD?
• What are the forecasted sales of JYNARQUE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to JYNARQUE for CKD?
• Which are the late-stage emerging therapies under development for the treatment of CKD?